KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Asset Writedowns and Impairment (2016 - 2026)

Pfizer has reported Asset Writedowns and Impairment over the past 18 years, most recently at $32.0 million for Q1 2026.

  • Quarterly Asset Writedowns and Impairment fell 85.71% to $32.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$192.0 million through Mar 2026, down 132.0% year-over-year, with the annual reading at $3.0 billion for FY2023, 445.45% up from the prior year.
  • Asset Writedowns and Impairment was $32.0 million for Q1 2026 at Pfizer, up from -$577.0 million in the prior quarter.
  • Over five years, Asset Writedowns and Impairment peaked at $2.5 billion in Q4 2023 and troughed at -$577.0 million in Q4 2025.
  • The 5-year median for Asset Writedowns and Impairment is $200.0 million (2022), against an average of $310.0 million.
  • Year-over-year, Asset Writedowns and Impairment skyrocketed 770.97% in 2023 and then plummeted 85.71% in 2026.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $200.0 million in 2022, then skyrocketed by 1150.5% to $2.5 billion in 2023, then tumbled by 90.4% to $240.0 million in 2024, then crashed by 340.42% to -$577.0 million in 2025, then surged by 105.55% to $32.0 million in 2026.
  • Per Business Quant, the three most recent readings for PFE's Asset Writedowns and Impairment are $32.0 million (Q1 2026), -$577.0 million (Q4 2025), and $260.0 million (Q3 2025).